Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
10/19/20177:05AMGLOBEGeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodi...
SALT LAKE CITY, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced new positive results for the GeneSight® test in patients with Generalized Anxiety Disorder (GAD).  The study found that GeneSight guided treatment statistically significantly... More...>>
10/18/20177:00AMGLOBEMyriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza® (olaparib...
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplementary premarket approval (sPMA) application for BRACAnalysis CDx® to be used as... More...>>
10/02/20177:05AMGLOBEMyriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Mont...
SALT LAKE CITY, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during Breast Cancer Awareness Month.  As the second leading form... More...>>
10/02/20177:05AMPRNUSMyriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Mont...
Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month PR Newswire SALT LAKE CITY, Oct. 2, 2017 SALT LAKE CITY, Oct. 2, 2017 /PRNewswire/ -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, continues... More...>>
09/15/20177:05AMGLOBEMyriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Societ...
SALT LAKE CITY, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors (NSGC) in Columbus... More...>>
09/12/20177:05AMGLOBEMyriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
SALT LAKE CITY, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from three studies at the National Society of Genetic Counselors (NSGC) Annual Conference to be held September 13-16, 2017, in... More...>>
09/07/20177:05AMPRNUSHereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month Eligible Patients Can Use the myRisk® Hereditary Cancer Test to Help Improve Their Care and Potentially Prevent Cancer in Their Family Members PR Newswire SALT LAKE CITY, Sept. 7, 2017 SALT LAKE... More...>>
09/05/20174:05PMGLOBEMyriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer Testing
SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore™, a new clinically validated precision medicine tool to enhance its myRisk® Hereditary Cancer test. riskScore quantifies... More...>>
08/30/20177:05AMGLOBEMyriad Genetics to Present at the 2017 Morgan Stanley Global Healthcare Conference
SALT LAKE CITY, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 10:35 a.m. ET on September 12, 2017, at... More...>>
08/29/20174:05PMGLOBEMyriad Genetics to Present at the 2017 Wells Fargo Healthcare Conference
SALT LAKE CITY, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Wells Fargo Healthcare Conference at 8:50 a.m. ET on September 7, 2017, at the Westin... More...>>
08/17/20174:15PMGLOBEEndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem
SALT LAKE CITY, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Palmetto GBA, the Medicare contractor who oversees the MolDx program and Anthem, Inc., one of the largest private insurers in the country, have announced... More...>>
08/08/20174:05PMGLOBEMyriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results
Total Revenues of $200.5 Million Up 8 PercentGAAP Diluted EPS was $0.19 and Adjusted EPS of $0.30Record Hereditary Cancer Demand and 86 Percent of Revenue Under Long-Term ContractCompany Issues Fiscal Year 2018 and Fiscal First-Quarter 2018 Financial Guidance SALT LAKE CITY, Aug. 08, 2017 (GLOBE NEWSWIRE) --  Myriad Genetics... More...>>
07/28/201711:16AMGLOBEMyriad to Announce Fiscal Fourth-Quarter 2017 Financial Results on August 8, 2017
SALT LAKE CITY, July 28, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 8, 2017.  During the call, Mark C. Capone, president and CEO and Bryan... More...>>
06/19/20177:05AMGLOBEVirginia C. Drosos, President of Assurex Health, Receives the EY Entrepreneur of the Year 2017 Award in Ohio Valley Region
SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Virginia (“Gina”) C. Drosos, president of Assurex Health, a wholly-owned subsidiary of Myriad Genetics, has received the EY Entrepreneur of the Year... More...>>
06/15/20177:05AMGLOBECrescendo Bioscience Announces Results from a Meta-Analysis of Studies with Vectra® DA at the 2017 Annual European Congress ...
SALT LAKE CITY, June 15, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra® DA test to predict joint damage were presented at the... More...>>
06/08/20177:05AMGLOBECrescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumat...
SALT LAKE CITY, June 08, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA test will be presented at the European League Against Rheumatism (EULAR) meeting being held June 14-17, 2017, in Madrid. ... More...>>
06/04/20177:30AMGLOBEMyriad’s BRACAnalysis CDx® Test Identified Patients with Metastatic Breast Cancer Who Benefited from Treatment with Olapar...
SALT LAKE CITY, June 04, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® companion diagnostic test successfully identified BRCA-mutated patients with HER2- metastatic breast cancer in the OlympiAD... More...>>
06/02/20174:05PMGLOBEMyriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield of California, Humana, Inc., and multiple... More...>>
06/02/20177:05AMGLOBEMyriad Genetics Announces Results from a Large 2,000 Patient Clinical Utility Study of Its myRisk® Hereditary Cancer Test at...
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk® Hereditary Cancer test, which will be featured in three poster presentations... More...>>
05/31/20174:05PMGLOBEMyriad Genetics to Present at the 2017 William Blair Growth Stock Conference
SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20171019 14:40:59